XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer
XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer
复制标题
DOI：
10.1093/abbs/gmp027
复制
发表时间：
2009-05-01
影响因子：
3.7
通讯作者：
Zhou, Yingfeng
中科院分区：
文献类型：
--
作者：
Feng, Jifeng;Sun, Xinchen;Zhou, Yingfeng
DNA 修复能力 (DRC) 与癌细胞对铂类化疗的敏感性相关。我们假设DNA修复基因XPA（色素性干皮病A组）和XPG（色素性干皮病G组）（ERCC5，切除修复交叉互补组5）的遗传多态性导致DNA修复效率的个体间差异，可能预测晚期非小细胞肺癌（NSCLC）患者对铂类药物的临床反应。在这项研究中，我们发现 XPA A23G 多态性的 A -> G 变化显着增加了对铂类化疗的反应。 XPG His46His 多态性与治疗反应降低相关，但不具有统计学意义。
DNA repair capacity (DRC) is correlated with sensitivity of cancer cells toward platinum-based chemotherapy. We hypothesize that genetic polymorphisms in DNA repair gene XPA (xeroderma pigmentosum group A) and XPG (xeroderma pigmentosum group G) (ERCC5, excision repair cross-complementation group 5), which result in inter-individual differences in DNA repair efficiency, may predict clinical response to platinum agents in advanced non-small cell lung cancer (NSCLC) patients. In this study, we find that the A -> G change of XPA A23G polymorphism significantly increased response to platinum-based chemotherapy. Polymorphism in XPG His46His was associated with a decreased treatment response, but was not statistically significant.